CVS Caremark®

|  |
| --- |
| Reference number(s) |
| 2368-A |

# Specialty Guideline Management Thalomid

## Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

| Brand Name | Generic Name |
| --- | --- |
| Thalomid | thalidomide |

## Indications

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

### FDA-Approved Indications1

* Thalomid in combination with dexamethasone is indicated for the treatment of patients with newly diagnosed multiple myeloma (MM).
* Erythema Nodosum Leprosum (ENL)
  + Acute treatment of the cutaneous manifestations of moderate to severe ENL.
  + Maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence

#### Limitations of Use

Thalomid is not indicated as monotherapy for ENL treatment in the presence of moderate to severe neuritis.

### Compendial Uses2-5

* Multiple Myeloma
* Multicentric Castleman disease
* Aphthous stomatitis
* Kaposi sarcoma
* Chronic graft-versus-host disease
* Crohn’s disease
* Histiocytic neoplasms
  + Langerhans cell histiocytosis
  + Rosai-Dorfman disease
* Pediatric Medulloblastoma

All other indications are considered experimental/investigational and not medically necessary.

## Coverage Criteria

### Multiple Myeloma1-5

Authorization of 12 months may be granted for treatment of multiple myeloma.

### Erythema Nodosum Leprosum1

Authorization of 12 months may be granted for treatment and prevention of erythema nodosum leprosum.

### Crohn’s Disease2

Authorization of 12 months may be granted for treatment of Crohn’s disease.

### Kaposi Sarcoma3

Authorization of 12 months may be granted for treatment of Kaposi sarcoma as subsequent therapy.

### Chronic Graft-versus-Host Disease2

Authorization of 12 months may be granted for treatment of chronic graft-versus-host disease.

### Multicentric Castleman Disease3

Authorization of 12 months may be granted for treatment of multicentric Castleman disease.

### Aphthous Stomatitis2,5

Authorization of 12 months may be granted for treatment of AIDS-related aphthous stomatitis and recurrent aphthous stomatitis in immunocompromised members.

### Histiocytic Neoplasms3

Authorization of 12 months may be granted for treatment of histiocytic neoplasms, including Langerhans cell histiocytosis and Rosai-Dorfman disease, as a single agent.

### Pediatric Medulloblastoma3

Authorization of 12 months may be granted for treatment of recurrent or progressive pediatric medulloblastoma as part of MEMMAT (thalidomide, celecoxib, fenofibrate, etoposide, cyclophosphamide, bevacizumab) regimen.

## Continuation of Therapy

### Multiple Myeloma, Multicentric Castleman Disease, Histiocytic Neoplasms, Kaposi sarcoma, and Pediatric Medulloblastoma

Authorization of 12 months may be granted for continued treatment in members requesting reauthorization for multiple myeloma, multicentric Castleman Disease, histiocytic neoplasms, Kaposi sarcoma, or peditric medulloblastoma when there is no evidence of unacceptable toxicity or disease progression while on the current regimen.

### All Other Indications

Authorization of 12 months may be granted for continued treatment in members requesting reauthorization for an indication listed in the coverage criteria section, other than multiple myeloma, multicentric Castleman disease, histiocytic neoplasms, Kaposi sarcoma, or pediatric medulloblastoma who have improvement in symptoms and no unacceptable toxicity.

## References

1. Thalomid [package insert]. Summit, NJ: Celgene Corporation; March 2023.
2. AHFS Drug Information. (Adult and Pediatric) Bethesda, MD. American Society of Health System Pharmacists, Inc. Electronic version. Updated October 2, 2024. Available with subscription. URL: http://online.lexi.com/lco. Accessed October 8, 2024.
3. The NCCN Drugs & Biologics Compendium® © 2024 National Comprehensive Cancer Network, Inc. http://www.nccn.org. Accessed October 8, 2024.
4. DRUGDEX® System (electronic version). Micromedex Truven Health Analytics, Greenwood Village, Colorado, USA. Available at: http://www.micromedexsolutions.com. Accessed October 8, 2024.
5. Lexicomp Online, Lexi-Drugs Online. Waltham, MA: UpToDate, Inc.; Updated October 2, 2023. https://online.lexi.com. Accessed October 8, 2024.